<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=us-ascii">
<meta name="Generator" content="Microsoft Word 14 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Tahoma;
panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
{font-family:Garamond;
panose-1:2 2 4 4 3 3 1 1 8 3;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:purple;
text-decoration:underline;}
p
{mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
{mso-style-priority:34;
margin-top:0in;
margin-right:0in;
margin-bottom:10.0pt;
margin-left:.5in;
line-height:115%;
font-size:11.0pt;
font-family:"Calibri","sans-serif";}
p.Default, li.Default, div.Default
{mso-style-name:Default;
mso-style-priority:99;
margin:0in;
margin-bottom:.0001pt;
text-autospace:none;
font-size:12.0pt;
font-family:"Times New Roman","serif";
color:black;}
span.EmailStyle20
{mso-style-type:personal;
font-family:"Calibri","sans-serif";
color:#1F497D;}
span.EmailStyle21
{mso-style-type:personal;
font-family:"Calibri","sans-serif";
color:#1F497D;}
span.EmailStyle22
{mso-style-type:personal;
font-family:"Calibri","sans-serif";
color:#1F497D;}
span.EmailStyle23
{mso-style-type:personal;
font-family:"Calibri","sans-serif";
color:#1F497D;}
span.EmailStyle24
{mso-style-type:personal-reply;
font-family:"Calibri","sans-serif";
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:501819341;
mso-list-type:hybrid;
mso-list-template-ids:746327614 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;}
@list l0:level2
{mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l0:level3
{mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l0:level4
{mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l0:level5
{mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l0:level6
{mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l0:level7
{mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l0:level8
{mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l0:level9
{mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l1
{mso-list-id:767388839;
mso-list-type:hybrid;
mso-list-template-ids:10511558 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;}
@list l1:level2
{mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l1:level3
{mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l1:level4
{mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l1:level5
{mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l1:level6
{mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l1:level7
{mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l1:level8
{mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l1:level9
{mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l2
{mso-list-id:2063170767;
mso-list-type:hybrid;
mso-list-template-ids:1576171576 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l2:level1
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;
font-family:Symbol;}
@list l2:level2
{mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l2:level3
{mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l2:level4
{mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l2:level5
{mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l2:level6
{mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l2:level7
{mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l2:level8
{mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l2:level9
{mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="blue" vlink="purple">
<div class="WordSection1">
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D">Dear Colleagues,
<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D">Sue Linder-Linsley, Executive Director and CEO of the Veterans Association Research Corporation in Dallas is interested in being part of a collaboration for
several funding opportunities regarding veterans. Please review the list below to see if anyone at your institution may be interested in a specific project. You may respond directly to Sue or to me, either way. Thank you.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D"><o:p> </o:p></span></p>
<div>
<div style="border:none;border-top:solid #B5C4DF 1.0pt;padding:3.0pt 0in 0in 0in">
<p class="MsoNormal"><b><span style="font-size:10.0pt;font-family:"Tahoma","sans-serif"">From:</span></b><span style="font-size:10.0pt;font-family:"Tahoma","sans-serif""> Linder-Linsley, Sue E. [mailto:Sue.Linder-Linsley@va.gov]
<br>
<b>Sent:</b> Tuesday, April 30, 2013 11:47 AM<br>
<b>To:</b> Mason, Linda<br>
<b>Subject:</b> FW: JUST RELEASED! FY13 DOD CDMRP Program Pre-Announcements<o:p></o:p></span></p>
</div>
</div>
<p class="MsoNormal"><o:p> </o:p></p>
<p class="MsoNormal"><o:p> </o:p></p>
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D">Linda:<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D">It was great meeting you at the NCURA V meetings last week. I am willing to volunteer help with anything I can so keep me in mind.
<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D">I am following up to see if we can jump start a collaboration. Below are funding opportunities I forwarded to our researchers last week. Let me know if you
have any researchers who may be interested in a join proposal and I will try to find someone on our side. I am open to the VA submitting as the prime but it would be great to be included as a sub /participant. I look forward to our first collaboration. These
just happen to be DOD but we are interested in all funding sources.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D">Sue<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:"Garamond","serif";color:#0070C0">Sue E. Linder-Linsley, MA<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:"Garamond","serif";color:#0070C0">Executive Director and CEO<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:"Garamond","serif";color:#0070C0">Dallas VA Research Corporation (DVARC)
<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:"Garamond","serif";color:#0070C0">4500 S. Lancaster Rd. Bldg 43, Suite 124 or PO Box 516
<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:"Garamond","serif";color:#0070C0">Dallas TX 75216-7167 Lancaster TX 75146-0516
<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:"Garamond","serif";color:#0070C0">214-857-0351 <o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:"Garamond","serif";color:#0070C0"><a href="mailto:Sue.Linder-Linsley@va.gov">Sue.Linder-Linsley@va.gov</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:"Garamond","serif";color:#0070C0"><a href="http://www.dvarc.org">www.dvarc.org</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D"><o:p> </o:p></span></p>
<p class="MsoNormal"><o:p> </o:p></p>
<p class="MsoNormal"><o:p> </o:p></p>
<p class="MsoNormal"><span style="font-size:11.0pt">The Fiscal Year 2013 (FY13) Defense Appropriations Act provides research funding for the peer reviewed programs managed by the Department of Defense (DOD) office of Congressionally Directed Medical Research
Programs (CDMRP). <o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt">This e-mail is to notify the research community of the recently released pre-announcements from the following programs:
<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt"><o:p> </o:p></span></p>
<p class="MsoNormal"><i><span style="font-size:11.0pt">Autism Research Program (ARP)<o:p></o:p></span></i></p>
<p class="MsoNormal"><i><span style="font-size:11.0pt">Bone Marrow Failure Research Program (BMFRP)<o:p></o:p></span></i></p>
<p class="MsoNormal"><i><span style="font-size:11.0pt">Duchenne Muscular Dystrophy Research Program (DMDRP)<o:p></o:p></span></i></p>
<p class="MsoNormal"><i><span style="font-size:11.0pt">Lung Cancer Research Program (OCRP)<o:p></o:p></span></i></p>
<p class="MsoNormal"><i><span style="font-size:11.0pt">Multiple Sclerosis Research Program (MSRP)<o:p></o:p></span></i></p>
<p class="MsoNormal"><i><span style="font-size:11.0pt">Ovarian Cancer Research Program (OCRP)<o:p></o:p></span></i></p>
<p class="MsoNormal"><i><span style="font-size:11.0pt">Peer Reviewed Medical Research Program (PRMRP)<o:p></o:p></span></i></p>
<p class="MsoNormal"><span style="font-size:11.0pt"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt">Descriptions of each of the funding opportunities, eligibility, key mechanism elements, and funding can be found in the respective Program pre-announcement. FY13 pre-announcements can be found in the CDMRP
home page features at </span><a href="http://cdmrp.army.mil"><span style="font-size:11.0pt;color:purple">http://cdmrp.army.mil</span></a><span style="font-size:11.0pt">.
<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:10.0pt">----------------------------------------------------------------------<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt">ARP at </span><a href="http://cdmrp.army.mil/pubs/press/2013/13arppreann.shtml"><span style="font-size:11.0pt">http://cdmrp.army.mil/pubs/press/2013/13arppreann.shtml</span></a><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt">BMFRP at </span><a href="http://cdmrp.army.mil/pubs/press/2013/13bmfrppreann.shtml"><span style="font-size:11.0pt">http://cdmrp.army.mil/pubs/press/2013/13bmfrppreann.shtml</span></a><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt">DMDRP at </span><a href="http://cdmrp.army.mil/pubs/press/2013/13dmdrppreann.shtml"><span style="font-size:11.0pt">http://cdmrp.army.mil/pubs/press/2013/13dmdrppreann.shtml</span></a><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt">LCRP at </span><a href="http://cdmrp.army.mil/pubs/press/2013/13lcrppreann.shtml"><span style="font-size:11.0pt">http://cdmrp.army.mil/pubs/press/2013/13lcrppreann.shtml</span></a><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt">MSRP at </span><a href="http://cdmrp.army.mil/pubs/press/2013/13msrppreann.shtml"><span style="font-size:11.0pt">http://cdmrp.army.mil/pubs/press/2013/13msrppreann.shtml</span></a><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt">OCRP at </span><a href="http://cdmrp.army.mil/pubs/press/2013/13ocrppreann.shtml"><span style="font-size:11.0pt">http://cdmrp.army.mil/pubs/press/2013/13ocrppreann.shtml</span></a><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt">PRMRP at </span><a href="http://cdmrp.army.mil/pubs/press/2013/13prmrppreann.shtml"><span style="font-size:11.0pt">http://cdmrp.army.mil/pubs/press/2013/13prmrppreann.shtml</span></a><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:10.0pt">----------------------------------------------------------------------<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt">Subsequent notifications will be sent when the program announcements/funding opportunities are released.
<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt">Please do not respond directly to this message. To be added or removed from this email list please send an email to
<a href="mailto:help@cdmrp.org">help@cdmrp.org</a>.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt">The Fiscal Year 2013 (FY13) Defense Appropriations Act provides research funding for the peer reviewed programs managed by the Department of Defense (DOD) office of Congressionally Directed Medical Research
Programs (CDMRP). <o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt">This e-mail is to notify the research community of the recently released pre-announcements from the following programs:
<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt"><o:p> </o:p></span></p>
<p class="MsoNormal"><i><span style="font-size:11.0pt">Amyotrophic Lateral Sclerosis Research Program (ALSRP)<o:p></o:p></span></i></p>
<p class="MsoNormal"><i><span style="font-size:11.0pt">Breast Cancer Research Program (BCRP)<o:p></o:p></span></i></p>
<p class="MsoNormal"><i><span style="font-size:11.0pt">Gulf War Illness Research Program (GWIRP)<o:p></o:p></span></i></p>
<p class="MsoNormal"><i><span style="font-size:11.0pt">Neurofibromatosis Research Program (NFRP)<o:p></o:p></span></i></p>
<p class="MsoNormal"><i><span style="font-size:11.0pt">Prostate Cancer Research Program (PCRP)<o:p></o:p></span></i></p>
<p class="MsoNormal"><i><span style="font-size:11.0pt">Tuberous Sclerosis Complex Research Program (TSCRP)</span></i><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt">Descriptions of each of the funding opportunities, eligibility, key mechanism elements, and funding can be found in the respective Program pre-announcement. FY13 pre-announcements can be found in the CDMRP
home page features at </span><a href="http://cdmrp.army.mil"><span style="font-size:11.0pt;color:purple">http://cdmrp.army.mil</span></a><span style="font-size:11.0pt">.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:10.0pt">----------------------------------------------------------------------<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt">ALSRP at </span><a href="http://cdmrp.army.mil/pubs/press/2013/13alsrppreann.shtml"><span style="font-size:11.0pt">http://cdmrp.army.mil/pubs/press/2013/13alsrppreann.shtml</span></a><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt">BCRP at </span><a href="http://cdmrp.army.mil/pubs/press/2013/13bcrppreann.shtml"><span style="font-size:11.0pt">http://cdmrp.army.mil/pubs/press/2013/13bcrppreann.shtml</span></a><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt">GWIRP at </span><a href="http://cdmrp.army.mil/pubs/press/2013/13gwirppreann.shtml"><span style="font-size:11.0pt">http://cdmrp.army.mil/pubs/press/2013/13gwirppreann.shtml</span></a><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt">NFRP at </span><a href="http://cdmrp.army.mil/pubs/press/2013/13nfrppreann.shtml"><span style="font-size:11.0pt">http://cdmrp.army.mil/pubs/press/2013/13nfrppreann.shtml</span></a><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt">PCRP at </span><a href="http://cdmrp.army.mil/pubs/press/2013/13pcrppreann.shtml"><span style="font-size:11.0pt">http://cdmrp.army.mil/pubs/press/2013/13pcrppreann.shtml</span></a><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt">TSCRP at </span><a href="http://cdmrp.army.mil/pubs/press/2013/13tscrppreann.shtml"><span style="font-size:11.0pt">http://cdmrp.army.mil/pubs/press/2013/13tscrppreann.shtml</span></a><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:10.0pt">----------------------------------------------------------------------<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt">Subsequent notifications will be sent when the program announcements/funding opportunities are released.
<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt">Please do not respond directly to this message. To be added or removed from this email list please send an email to
<a href="mailto:help@cdmrp.org">help@cdmrp.org</a>.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:8.5pt"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:8.5pt;color:#1F497D"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D"><o:p> </o:p></span></p>
<p class="MsoNormal" align="center" style="text-align:center;background:white"><b><span style="font-family:"Arial","sans-serif"">NEWS RELEASE<o:p></o:p></span></b></p>
<p class="MsoNormal" align="center" style="text-align:center;background:white"><span style="font-family:"Arial","sans-serif""><o:p> </o:p></span></p>
<p class="MsoNormal" align="center" style="text-align:center;background:white"><span style="font-family:"Arial","sans-serif""><o:p> </o:p></span></p>
<p class="MsoNormal" align="center" style="text-align:center;background:white"><b><span style="font-family:"Arial","sans-serif"">Department of Defense Gulf War Illness Research Program<br>
Anticipated Funding Opportunities for Fiscal Year 2013 (FY13)<o:p></o:p></span></b></p>
<p class="MsoNormal" style="background:white"><span style="font-family:"Arial","sans-serif""><o:p> </o:p></span></p>
<p class="MsoNormal" style="background:white"><b><span style="font-family:"Arial","sans-serif"">The FY13 Defense Appropriations Act provides $20 million (M) to the Department of Defense Gulf War Illness Research Program (GWIRP)
</span></b><span style="font-family:"Arial","sans-serif"">to support innovative, high-impact research into Gulf War Illness (GWI). The Department of Defense Gulf War Illness Research Program (GWIRP) is administered by the US Army Medical Research and Materiel
Command (USAMRMC) through the Office of Congressionally Directed Medical Research Programs (CDMRP).<o:p></o:p></span></p>
<p class="MsoNormal" style="background:white"><span style="font-family:"Arial","sans-serif""><o:p> </o:p></span></p>
<p class="MsoNormal" style="background:white"><span style="font-family:"Arial","sans-serif"">The GWIRP is providing this information to allow investigators time to plan and develop applications. FY13 GWIRP program announcements and general application instructions
for the following award mechanisms are anticipated to be posted on Grants.gov in May 2013. This pre-announcement should not be construed as an obligation by the government. Application submission dates are not available until the Program Announcements are
released.<o:p></o:p></span></p>
<p class="MsoNormal" style="background:white"><span style="font-family:"Arial","sans-serif""><o:p> </o:p></span></p>
<p class="MsoNormal" style="background:white"><b><span style="font-family:"Arial","sans-serif"">Investigator-Initiated Research Award<o:p></o:p></span></b></p>
<p class="MsoNormal" style="background:white"><span style="font-family:"Arial","sans-serif"">Independent investigators at all academic levels are eligible to apply.<o:p></o:p></span></p>
<p class="MsoListParagraph" style="mso-margin-top-alt:0in;margin-right:0in;margin-bottom:0in;margin-left:17.3pt;margin-bottom:.0001pt;text-indent:-13.7pt;line-height:normal;mso-list:l0 level1 lfo2;text-autospace:none">
<![if !supportLists]><span style="font-size:12.0pt;font-family:Symbol;color:black"><span style="mso-list:Ignore">·<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span style="font-size:12.0pt;font-family:"Arial","sans-serif";color:black">Supports new ideas in basic and clinical developmental research focusing on Gulf War Illness (GWI).<o:p></o:p></span></p>
<p class="MsoListParagraph" style="mso-margin-top-alt:0in;margin-right:0in;margin-bottom:0in;margin-left:17.3pt;margin-bottom:.0001pt;text-indent:-13.7pt;line-height:normal;mso-list:l0 level1 lfo2;text-autospace:none">
<![if !supportLists]><span style="font-size:12.0pt;font-family:Symbol;color:black"><span style="mso-list:Ignore">·<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span style="font-size:12.0pt;font-family:"Arial","sans-serif";color:black">Preliminary data are not required, and if provided, do not necessarily have to come from the GWI research field.<o:p></o:p></span></p>
<p class="MsoListParagraph" style="mso-margin-top-alt:0in;margin-right:0in;margin-bottom:0in;margin-left:17.3pt;margin-bottom:.0001pt;text-indent:-13.7pt;line-height:normal;mso-list:l0 level1 lfo2;text-autospace:none">
<![if !supportLists]><span style="font-size:12.0pt;font-family:Symbol;color:black"><span style="mso-list:Ignore">·<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span style="font-size:12.0pt;font-family:"Arial","sans-serif";color:black">Studies that provide outcomes clearly translatable to clinical use are encouraged.<o:p></o:p></span></p>
<p class="MsoListParagraph" style="mso-margin-top-alt:0in;margin-right:0in;margin-bottom:0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-13.5pt;line-height:normal;mso-list:l0 level1 lfo2;text-autospace:none">
<![if !supportLists]><span style="font-size:12.0pt;font-family:Symbol;color:black"><span style="mso-list:Ignore">·<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span style="font-size:12.0pt;font-family:"Arial","sans-serif";color:black">Clinical trials are not allowed under this mechanism.
<o:p></o:p></span></p>
<p class="MsoListParagraph" style="margin:0in;margin-bottom:.0001pt;line-height:normal;text-autospace:none">
<span style="font-size:12.0pt;font-family:"Arial","sans-serif";color:black">The maximum allowable funding for the entire period of performance is $600,000 for direct costs.<o:p></o:p></span></p>
<p class="MsoListParagraph" style="mso-margin-top-alt:0in;margin-right:0in;margin-bottom:0in;margin-left:.7pt;margin-bottom:.0001pt;line-height:normal;text-autospace:none">
<span style="font-size:12.0pt;font-family:"Arial","sans-serif";color:black">The maximum period of performance is 3 years.
<o:p></o:p></span></p>
<p class="MsoNormal" style="background:white"><span style="font-family:"Arial","sans-serif";color:black">More cost-effective studies not requesting the full funding amount are encouraged.<o:p></o:p></span></p>
<p class="MsoNormal" style="background:white"><span style="font-family:"Arial","sans-serif""><o:p> </o:p></span></p>
<p class="MsoNormal" style="margin-right:6.55pt"><b><span style="font-family:"Arial","sans-serif"">Innovative Treatment Evaluation Award
<o:p></o:p></span></b></p>
<p class="MsoNormal" style="margin-right:6.55pt"><span style="font-family:"Arial","sans-serif"">Independent investigators at all academic levels are eligible to apply.<o:p></o:p></span></p>
<p class="Default" style="margin-left:12.95pt;text-indent:-12.95pt;mso-list:l0 level1 lfo2">
<![if !supportLists]><span style="font-family:Symbol"><span style="mso-list:Ignore">·<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span style="font-family:"Arial","sans-serif"">Supports exploratory or small-scale studies evaluating potential treatments not previously studied in GWI.
<o:p></o:p></span></p>
<p class="Default" style="margin-left:12.95pt;text-indent:-12.95pt;mso-list:l2 level1 lfo4">
<![if !supportLists]><span style="font-family:Symbol"><span style="mso-list:Ignore">·<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span style="font-family:"Arial","sans-serif"">Pilot Phase II or Phase I/II trial combinations are permitted.
<o:p></o:p></span></p>
<p class="Default" style="margin-left:12.95pt;text-indent:-12.95pt;mso-list:l2 level1 lfo4">
<![if !supportLists]><span style="font-family:Symbol"><span style="mso-list:Ignore">·<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span style="font-family:"Arial","sans-serif"">Preliminary data are
<u>not</u> required, though proposed studies must be supported by logical rationale.<o:p></o:p></span></p>
<p class="Default" style="margin-left:12.95pt;text-indent:-12.95pt;mso-list:l2 level1 lfo4">
<![if !supportLists]><span style="font-family:Symbol"><span style="mso-list:Ignore">·<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span style="font-family:"Arial","sans-serif"">Studies with clear potential to move forward to Phase II/III clinical trials are encouraged
<o:p></o:p></span></p>
<p class="Default"><span style="font-family:"Arial","sans-serif"">The maximum allowable funding for the entire period of performance is $450,000 for direct costs.<o:p></o:p></span></p>
<p class="Default"><span style="font-family:"Arial","sans-serif"">The maximum period of performance is 3 years.<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-right:6.55pt"><span style="font-family:"Arial","sans-serif"">More cost-effective studies not requesting the full funding amount are encouraged.<o:p></o:p></span></p>
<p class="MsoNormal" style="mso-margin-top-alt:0in;margin-right:6.55pt;margin-bottom:0in;margin-left:6.55pt;margin-bottom:.0001pt">
<b><span style="font-family:"Arial","sans-serif""><o:p> </o:p></span></b></p>
<p class="MsoNormal" style="margin-right:6.55pt"><b><span style="font-family:"Arial","sans-serif"">Clinical Trial Award<o:p></o:p></span></b></p>
<p class="MsoNormal" style="margin-right:6.55pt"><span style="font-family:"Arial","sans-serif"">Independent investigators at all academic levels are eligible to apply.<o:p></o:p></span></p>
<p class="Default" style="margin-left:12.25pt;text-indent:-12.25pt;mso-list:l1 level1 lfo6">
<![if !supportLists]><span style="font-family:Symbol"><span style="mso-list:Ignore">·<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span style="font-family:"Arial","sans-serif"">Supports larger, more definitive Phase II or III clinical trials focusing on treatments for GWI.
<o:p></o:p></span></p>
<p class="Default" style="margin-left:12.25pt;text-indent:-12.25pt;mso-list:l1 level1 lfo6">
<![if !supportLists]><span style="font-family:Symbol"><span style="mso-list:Ignore">·<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span style="font-family:"Arial","sans-serif"">Preliminary/preclinical data
<u>are required</u> indicating potential substantial benefit for veterans with GWI.
<o:p></o:p></span></p>
<p class="Default" style="margin-left:12.25pt;text-indent:-12.25pt;mso-list:l1 level1 lfo6">
<![if !supportLists]><span style="font-family:Symbol"><span style="mso-list:Ignore">·<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span style="font-family:"Arial","sans-serif"">Pilot or exploratory studies focusing on treatments lacking preclinical/preliminary data should submit to the Innovative Treatment Evaluation Award (see above).<o:p></o:p></span></p>
<p class="Default"><span style="font-family:"Arial","sans-serif"">The maximum allowable funding for the entire period of performance is $1,500,000 for direct costs.<o:p></o:p></span></p>
<p class="Default"><span style="font-family:"Arial","sans-serif"">The maximum period of performance is 4 years.
<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-right:6.55pt"><span style="font-family:"Arial","sans-serif"">More cost-effective studies not requesting the full funding amount are encouraged.<b><o:p></o:p></b></span></p>
<p class="MsoNormal" style="background:white"><span style="font-family:"Arial","sans-serif""><o:p> </o:p></span></p>
<p class="MsoNormal" style="background:white"><span style="font-family:"Arial","sans-serif"">All applications must conform to the final program announcements and application instructions that will be available for electronic downloading from the Grants.gov
website. The application package containing the required forms for each award mechanism will be found on Grants.gov. A listing of all USAMRMC funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.
<o:p></o:p></span></p>
<p class="MsoNormal" style="background:white"><span style="font-family:"Arial","sans-serif""><o:p> </o:p></span></p>
<p class="MsoNormal" style="background:white"><span style="font-family:"Arial","sans-serif"">A pre-application is required and must be submitted through the
<a href="http://cdmrp.org"><b><span style="color:black">CDMRP eReceipt website</span></b></a> (<a href="http://cdmrp.org">http://cdmrp.org</a>) prior to the pre-application deadline. Applications must be submitted through the federal government single-entry
portal, <a href="http://www.grants.gov"><b><span style="color:black">Grants.gov</span></b></a>.<o:p></o:p></span></p>
<p class="MsoNormal" style="background:white"><span style="font-family:"Arial","sans-serif""><o:p> </o:p></span></p>
<p class="MsoNormal" style="background:white"><span style="font-family:"Arial","sans-serif"">Submission deadlines are not available until the program announcements are released. Requests for email notification of the release of CDMRP program announcements
may be sent to <a href="mailto:help@cdmrp.org"><b><span style="color:black">help@cdmrp.org</span></b></a>. For more information about the GWIRP or other CDMRP-administered programs, please visit the
<a href="http://cdmrp.army.mil"><b><span style="color:black">CDMRP website</span></b></a> (<a href="http://cdmrp.army.mil">http://cdmrp.army.mil</a>).<o:p></o:p></span></p>
<p class="MsoNormal" style="background:white"><span style="font-family:"Arial","sans-serif""><o:p> </o:p></span></p>
<p class="MsoNormal" style="background:white"><span style="font-family:"Arial","sans-serif"">If you are not the correct person or no longer wish to receive these types of announcements please let us know and we will update our distribution list.<o:p></o:p></span></p>
<p class="MsoNormal" style="background:white"><span style="font-family:"Arial","sans-serif""><o:p> </o:p></span></p>
<p class="MsoNormal" style="background:white"><b><span style="font-family:"Arial","sans-serif"">Point of Contact:</span></b><span style="font-family:"Arial","sans-serif""><o:p></o:p></span></p>
<p class="MsoNormal" style="background:white"><span style="font-family:"Arial","sans-serif""><o:p> </o:p></span></p>
<p class="MsoNormal" style="text-autospace:none"><span style="font-family:"Arial","sans-serif"">CDMRP Public Affairs<br>
301-619-9783<br>
<a href="mailto:usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil">usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D"><o:p> </o:p></span></p>
</div>
</body>
</html>